Table 4.
Questionnaire scores regarding gut health, psychological distress and stress at baseline and after intervention with arabinoxylan (AX), placebo, and oat β-glucan (OBG). Data presented as median (IQR).
| AX (n = 17) * | Placebo (n = 17) | OBG (n = 15) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | End of Study |
p- value |
Baseline | End of Study |
p- Value |
Baseline | End of Study |
p- Value |
|
|
GSRS - Diarrha |
1.5 (1.0–2.8) |
1.3 (1.0–1.9) |
0.336 | 1.3 (1.0–2.7) |
1 (1.0–2.7) |
0.516 | 1.3 (1.0–2.0) |
1.3 (1.0–2.3) |
0.45 |
|
GSRS - Constipation |
1.3 (1.0–2.6) |
1.2 (1.0–2.9) |
0.242 | 1.3 (1.2–3.2) |
1.3 (1.0–2.8) |
0.824 | 1.3 (1.0–1.7) |
1.0 (1.0–2.0) |
>0.99 |
| HADS | 4 (2–5) |
3 ( 1–5.5) |
0.106 | 5.5 (3.3–9.5) |
5.5 (2.3–8) |
0.529 | 3 (2–5) |
5 (1–7) |
0.55 |
| PSS | 8 (4.3–12) |
6.5 (4.3–8.8) |
0.319 | 9.5 (6.3–14) |
10 (3–14) |
0.814 | 8 (4–12) |
6 (3–9) |
0.28 |
|
EuroQol
VAS |
85 (76–95) |
85 (80–90) |
0.621 | 83 (80–94) |
90 (76–95) |
0.762 | 90 (81–95) |
90 (80–95) |
0.36 |
|
EuroQol
Index |
0.86 (0.79–0.86) |
0.86 (0.79–0.86) |
0.875 | 0.86 (0.76–1) |
0.80 (0.76–1) |
0.594 | 0.93 (0.86–1) |
1 (0.86–1) |
0.83 |
GSRS – Gastrointestinal Symptoms Rating Scale; HADS – Hospital Anxiety and Depression Scale; PSS – Perceived Stress Scale; * 17 included in the group, though there are missing values for HADS (n = 1), EuroQol-VAS (n = 1) and EuroQol-index (n = 2), leaving categories with 16, 16 and 15 participants, respectively.